Enantioselective Total Synthesis of (−)‐Finerenone Using Asymmetric Transfer Hydrogenation

(−)‐Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. It contains an unusual dihydronaphthyridine core. We report a 6‐step synthesis of (−)‐finerenone, which features an enantiosel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerchen, Andreas, Gandhamsetty, Narasimhulu, Farrar, Elliot H. E., Winter, Nils, Platzek, Johannes, Grayson, Matthew N., Aggarwal, Varinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839499/
https://www.ncbi.nlm.nih.gov/pubmed/32890415
http://dx.doi.org/10.1002/anie.202011256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839499/
https://www.ncbi.nlm.nih.gov/pubmed/32890415
http://dx.doi.org/10.1002/anie.202011256

Ejemplares similares